300 related articles for article (PubMed ID: 33788825)
1. Allogeneic Natural Killer and Cytomegalovirus (CMV)-pp65 Pulsed Dendritic Cells Induced Complete Response Through 15 Months in a Patient with Recurrent Glioblastoma: A Case Study.
Gumrukcu S; Nguyen TX; White RL; Howell GT; Musikanth P
Am J Case Rep; 2021 Mar; 22():e931030. PubMed ID: 33788825
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
Reap EA; Suryadevara CM; Batich KA; Sanchez-Perez L; Archer GE; Schmittling RJ; Norberg PK; Herndon JE; Healy P; Congdon KL; Gedeon PC; Campbell OC; Swartz AM; Riccione KA; Yi JS; Hossain-Ibrahim MK; Saraswathula A; Nair SK; Dunn-Pirio AM; Broome TM; Weinhold KJ; Desjardins A; Vlahovic G; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Fecci PE; Mitchell DA; Sampson JH
Cancer Res; 2018 Jan; 78(1):256-264. PubMed ID: 29093005
[TBL] [Abstract][Full Text] [Related]
3. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
[No Abstract] [Full Text] [Related]
4. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.
Nair SK; De Leon G; Boczkowski D; Schmittling R; Xie W; Staats J; Liu R; Johnson LA; Weinhold K; Archer GE; Sampson JH; Mitchell DA
Clin Cancer Res; 2014 May; 20(10):2684-94. PubMed ID: 24658154
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
Hu JL; Omofoye OA; Rudnick JD; Kim S; Tighiouart M; Phuphanich S; Wang H; Mazer M; Ganaway T; Chu RM; Patil CG; Black KL; Shiao SL; Wang R; Yu JS
Clin Cancer Res; 2022 Feb; 28(4):689-696. PubMed ID: 34862245
[TBL] [Abstract][Full Text] [Related]
6. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
[TBL] [Abstract][Full Text] [Related]
7. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Haspels HN; Rahman MA; Joseph JV; Gras Navarro A; Chekenya M
Front Immunol; 2018; 9():1345. PubMed ID: 29967607
[TBL] [Abstract][Full Text] [Related]
10. Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Lamano JB; Quaggin-Smith JA; Horbinski CM; Tate MC; Grimm SA; Kumthekar PU; Bloch O
J Clin Neurosci; 2019 Jun; 64():18-21. PubMed ID: 30948314
[TBL] [Abstract][Full Text] [Related]
11. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T(helper) cell response.
Feuchtinger T; Opherk K; Bicanic O; Schumm M; Grigoleit GU; Hamprecht K; Jahn G; Handgretinger R; Lang P
Cytotherapy; 2010 Nov; 12(7):945-50. PubMed ID: 20230226
[TBL] [Abstract][Full Text] [Related]
14. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
Ghazi A; Ashoori A; Hanley PJ; Brawley VS; Shaffer DR; Kew Y; Powell SZ; Grossman R; Grada Z; Scheurer ME; Hegde M; Leen AM; Bollard CM; Rooney CM; Heslop HE; Gottschalk S; Ahmed N
J Immunother; 2012; 35(2):159-68. PubMed ID: 22306904
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
16. Retracted: Allogeneic Natural Killer and Cytomegalovirus (CMV)-pp65 Pulsed Dendritic Cells Induced Complete Response Through 15 Months in a Patient with Recurrent Glioblastoma: A Case Study.
Gumrukcu S; Nguyen TX; White RL; Howell GT; Musikanth P
Am J Case Rep; 2022 Jul; 23():e937680. PubMed ID: 35788133
[TBL] [Abstract][Full Text] [Related]
17. Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells.
Djaoud Z; David G; Bressollette C; Willem C; Rettman P; Gagne K; Legrand N; Mehlal S; Cesbron A; Imbert-Marcille BM; Retière C
J Immunol; 2013 Sep; 191(5):2708-16. PubMed ID: 23918974
[TBL] [Abstract][Full Text] [Related]
18. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
19. Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia.
Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; López J; Garcia-Noblejas A; Navarro D
J Med Virol; 2015 Sep; 87(9):1601-7. PubMed ID: 25802229
[TBL] [Abstract][Full Text] [Related]
20. Characterization of IFNγ-producing natural killer cells induced by cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation.
Jin F; Lin H; Gao S; Wang H; Yan H; Guo J; Hu Z; Jin C; Wang Y; Wang Z; Zhao Y; Liu Y; Zheng X; Tan Y; Li W; Dai Y; Yang Y
Oncotarget; 2017 Jan; 8(1):51-63. PubMed ID: 27980216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
